AI Article Synopsis
- Clozapine, an atypical antipsychotic, is associated with significant weight gain in patients.
- A study involving monozygotic twins with schizophrenia treated with clozapine over 5.5 years revealed substantial weight increases in both twins (53.1 kg and 48.2 kg).
- The findings imply that genetic factors may play a significant role in the weight gain caused by clozapine treatment.
Article Abstract
Clozapine is an atypical antipsychotic known to cause considerable weight gain. The extent to which genetic factors determine weight gain is unknown. Here we report on a pair of female monozygotic twins concordant for schizophrenia and mild mental retardation who were treated with clozapine over 5.5 years. One twin gained a total of 53.1 kg and had a weight of 107.5 kg (BMI=38.1 kg/m2) at the end of the observation period. The other twin gained a total of 48.2 kg and finally had a weight of 100.4 kg (BMI=33.8 kg/m2). Because both patients experienced considerable weight gain during treatment, our observation suggests that the antipsychotic-induced weight gain is under strong genetic control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.psychres.2004.02.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!